Skip to main content
. Author manuscript; available in PMC: 2021 Sep 21.
Published in final edited form as: Cancer Res. 2017 Jul 28;77(19):5409–5418. doi: 10.1158/0008-5472.CAN-17-0835

Figure 1.

Figure 1.

Interactions hypothesized in the compartmental model: positive interactions are represented with arrows, negative ones with flat ends. The BRAFi (targeted to the tumor) inhibits growth in the drug-sensitive portion of the tumor (S) and induces activation of normal stroma (F). In turn, reactive stroma (A) promotes growth in the drug-tolerant portion of the tumor (R). The stroma-targeted inhibitor FAKi dampens the effect of stromal-induced growth promotion. Upon removal of BRAFi the tumor reacquires sensitivity to the drug and the stroma renormalizes (grey arrows).